Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Part of paid clinical trials in Anchorage, Alaska.
- Sponsor
- Incyte Corporation
- Study ID
- NCT07214779
- Phase
- PHASE3
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- INCB123667 — DRUGOral; tablet
- Investigator's choice of chemotherapy — DRUGThe investigator will select the chemotherapy in accordance with the protocol-defined requirements. The possible choices as defined by the protocol:
Study Details
The purpose of this study is to evaluate INCB123667 versus investigator's choice of chemotherapy in participants with platinum-resistant ovarian cancer with cyclin E1 overexpression.
Key Dates
- First listed
- Oct 9, 2025
- Start date
- Dec 9, 2025
- Status verified
- Jul 2026
- Primary completion
- Nov 15, 2028
- Completion
- May 14, 2029
Study Design
- Enrollment
- 466 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Treatment Group A (TGA)INCB123667 at the protocol-defined dose.
- Experimental: Treatment Group B (TGB)Investigator's choice of chemotherapy at the protocol-defined dose as defined by the protocol.
Primary Outcome Measure
Progression-Free Survival (PFS) by BICR [ Time Frame: Up to 2 years ]
Central Contacts
- Incyte Corporation Call Center (US)1.855.463.3463
- Incyte Corporation Call Center (ex-US)+800 00027423
Locations (39)
Find similar trials in Anchorage, AK
By condition
By specialty
By research site
Alaska Womens Cancer Care Akwcc· Anchorage, AKCity of Hope Medical Center· Duarte, CAVirginia K. Crosson Cancer Center At St. Jude Medical Center· Fullerton, CAUniversity of California, San Diego-Moores Cancer Center· La Jolla, CAValkyrie Clinical Trials· Los Angeles, CAVentura County Hematology· Oxnard, CA
Related Studies
- Specimen and Data Study for Ovarian Cancer Early Detection and PreventionRecruiting · Northwestern University · Chicago, Illinois
- Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk WomenRecruiting · M.D. Anderson Cancer Center · Miami, Florida
- Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood SamplesRecruiting · Stanford University · Stanford, California
- Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic AnalysisRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland